Navigation Links
Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
Date:10/18/2007

ntibodies are in clinical development. MT103 (MEDI-538), the first antibody developed using the BiTE (R)technology platform to be clinically validated in Micromet's product pipeline, is being evaluated in a phase 1 clinical trial for the treatment of patients with non- Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in collaboration with AstraZeneca plc's subsidiary MedImmune, Inc. The second clinical stage antibody is adecatumumab (MT201), a human monoclonal antibody targeting EpCAM expressing tumors. Adecatumumab is being developed by Micromet in collaboration with Merck Serono in a phase 1b clinical trial evaluating MT201 in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody is MT293 (formerly D93), also known as TRC093, a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. MT293, which is currently being tested in a phase 1 clinical trial, is licensed to TRACON Pharmaceuticals, Inc. and is being developed for the treatment of patients with cancer and age-related macular degeneration. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual r
'/>"/>

SOURCE Micromet, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Infant receives first bloodless liver transplant
2. British MPs Say Prostate Cancer Receives Low Priority in the NHS
3. Fifth US Patient Receives Artificial Heart
4. Northfield Labs Receives FDA Comments
5. Abbott Receives CE Mark Certification
6. Zactima Receives Fast Track Designation By The FDA
7. East London Receives World Class New Private Hospital Facility
8. Brinda Karat Receives Legal Notice over Ramdev Issue
9. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
10. Medtronic’s Insulin Pump Receives Regulatory Approva
11. Aurobindo Receives Approval from USFDA for anti-AIDS drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... Harvard neuroscientists have made a discovery that turns 160 ... electrical insulating material long known to be essential for ... nerve cells, is not as ubiquitous as thought, according ... of the Harvard Stem Cell Institute (HSCI) and the ... collaboration with Professor Jeff Lichtman, of Harvard,s Department of ...
(Date:4/18/2014)... did it make you feel? According to psychologists, remembering ... as how sad you were or how embarrassed you ... can,t stop thinking about it. , When these ... the memories, rather than how you felt, is a ... effects of these memories, a new study suggests. , ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... This news release is available in French . ... breakthrough could revolutionize surgical practice and regenerative medicine. A ... Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur ... and Paris 13), has just demonstrated that the principle ... used in vivo to repair soft-tissue organs and tissues. ...
(Date:4/17/2014)... The presence of chronic inflammation in benign ... prostate cancer, and this association was found even ... according to a study published in Cancer ... the American Association for Cancer Research. , An ... participants of the placebo arm of the Prostate ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... at Jefferson have found a mechanism by which a ... makes breast cancer more aggressive. Publishing in the ... prolactin, a pituitary hormone that normally stimulates breast development ... oncogene called BCL6. The BCL6 protein has previously been ...
... Predictive, Preventive and Personalised Medicine have founded, as the ... Creating a reliable scientific platform for the optimal combination ... laboratory medicine, the EPMA Journal will highlight ... and personalised medicine. The EPMA Journal ...
... , CARROLLTON, Texas , Feb. ... (AAUCM) has begun a sponsorship of the A-Claim™ medical payment ... , A-Claim ( www.A-Claim.com ) is a proprietary medical payment ... Carrollton, Texas , that is changing the way physicians, hospitals ...
... Nixon declared a "War on Cancer," the disease still claims ... expenditure of $5 billion by the U.S. government on research ... made since Nixon,s call to action in 1971, cancer research ... which is only increasing as scientists discover new drugs and ...
... ... As Strauss Radio Strategies continues to grow and expand, it has ... signing onto the GSA Schedule - the federal government procurement system. Government ... base and the addition to the GSA schedule will greatly facilitate the ...
... ... , ... February 3, 2010 -- Governance, Risk and Compliance (GRC) leader MetricStream ... over 2008 combined with record profits. MetricStream’s growth was fueled by companies prioritizing their need ...
Cached Medicine News:Health News:Springer publishes new journal in predictive, preventive and personalized medicine 2Health News:Urgent Care Providers Tout Benefits of A-Claim Medical Payment Solution 2Health News:Urgent Care Providers Tout Benefits of A-Claim Medical Payment Solution 3Health News:Developing a cyberinfrastructure for comparative effectiveness in cancer research 2Health News:Developing a cyberinfrastructure for comparative effectiveness in cancer research 3Health News:Developing a cyberinfrastructure for comparative effectiveness in cancer research 4Health News:Developing a cyberinfrastructure for comparative effectiveness in cancer research 5Health News:Strauss Radio Strategies - The Nation's Leading Radio Media Relations Firm - Expands Government Business with Award on GSA Schedule 2Health News:Strauss Radio Strategies - The Nation's Leading Radio Media Relations Firm - Expands Government Business with Award on GSA Schedule 3Health News:MetricStream Achieves Record Revenue Growth in 2009 with Global Customer Adoption of its Enterprise GRC Platform and Solutions 2Health News:MetricStream Achieves Record Revenue Growth in 2009 with Global Customer Adoption of its Enterprise GRC Platform and Solutions 3Health News:MetricStream Achieves Record Revenue Growth in 2009 with Global Customer Adoption of its Enterprise GRC Platform and Solutions 4
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... 2011 Omnicell, Inc . (NASDAQ: ... and supply management solutions and analytics software for ... Hospital (RVH) selected Omnicell G4 solutions to ... Omnicell,s hallmark flexibility and functionality, RVH became the ...
... 26, 2011 PolyGel, the manufacturer of Orthopedic, ... long term exclusive distribution agreement with China National ... in Beijing, China, Sinopharm Foreign Trade is a ... (SINOPHARM Group). (Photo:   http://photos.prnewswire.com/prnh/20110726/NY40954 ...
Cached Medicine Technology:Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 2Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 3Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 4PolyGel Signs Long Term Exclusive Agreement With China's Largest Distributor of Healthcare Products 2
... The PK Super-Sect is a ... tissue removal with minimal thermal spread ... for superior hemostatis. It can be ... gland and/or bladder tumor. It is ...
... CS is a fully ... treatment system designed to ... unlimited flexibility. Cryocare CS ... specific physician needs through ...
... Oncura's SeedNet system is a minimally invasive ... to learn and simple to use, SeedNet ... the cryoablation process. SeedNet is the ... Ultra-thin needles, exclusive to the SeedNet system, ...
Medium Clip Appliers. American-made stainless steel, 6" long, curved tip. For use with VE-6-25 and VE-6-10 titanium surgical clips only....
Medicine Products: